Search

Search Constraints

You searched for: Author/Creator Little, M.

Search Results

2. AB0511 INTERNATIONAL CONSENSUS ON ANCA TESTING AND INTERPRETATION BEYOND SYSTEMIC VASCULITIS. (2nd June 2020)

3. Anti‐inflammatory effects of infliximab in mice are independent of tumour necrosis factor α neutralization. (23rd November 2016)

4. Anti‐inflammatory effects of infliximab in mice are independent of tumour necrosis factor α neutralization. (23rd November 2016)

5. BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION. (June 2017)

7. Contemporary treatment patterns and response in relapse/refractory cutaneous T-cell lymphoma (CTCL) in clinical practice in France, Germany Italy, Spain and the United Kingdom. (2019)

8. FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30‐POSITIVE (CD30+) CUTANEOUS T‐CELL LYMPHOMA (CTCL). (12th June 2019)

9. OP0053 Eular/ERA-EDTA Recommendations for The Management of Anca-Associated Vasculitis. (15th July 2016)

10. OP0124 Contextualising quality of life in ANCA associated vasculitis (AAV). (23rd January 2014)